文摘
A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline rong class="boldFont">1rong> suffered from modest cell potency (cellular IC50 = 0.71 渭M measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole rong class="boldFont">26rong> (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes.